Inovio Says China Partner Reported VGX-3100 Phase 3 Trial Met Primary Efficacy Endpoint in Cervical Dysplasia Patients

MT Newswires Live05-22

Inovio Pharmaceuticals (INO) said late Thursday that its China partner for VGX-3100, ApolloBio, revealed that the investigational immunotherapy met its primary efficacy endpoint in a phase 3 trial to treat cervical dysplasia, a precancerous condition that can progress to cervical cancer if left untreated.

The investigational DNA immunotherapy demonstrated overall favorable safety and tolerability profile, the company said.

ApolloBio will use trial results to support future regulatory submission of VGX-3100 in China, according to a statement.

Under the deal with ApolloBio, Inovio will receive up to $20 million upon achieving milestones related to the regulatory approval of the immunotherapy in certain territories, according to the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637357570?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637357570","market":"sh","top_or_hot":-1,"title":"Inovio Says China Partner Reported VGX-3100 Phase 3 Trial Met Primary Efficacy Endpoint in Cervical Dysplasia Patients","media":"MT Newswires Live","content":"<html><body><p> Inovio Pharmaceuticals (INO) said late Thursday that its China partner for VGX-3100, ApolloBio, revealed that the investigational immunotherapy met its primary efficacy endpoint in a phase 3 trial to treat cervical dysplasia, a precancerous condition that can progress to cervical cancer if left untreated.</p><p>The investigational DNA immunotherapy demonstrated overall favorable safety and tolerability profile, the company said.</p><p>ApolloBio will use trial results to support future regulatory submission of VGX-3100 in China, according to a statement.</p><p>Under the deal with ApolloBio, Inovio will receive up to $20 million upon achieving milestones related to the regulatory approval of the immunotherapy in certain territories, according to the company.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Says China Partner Reported VGX-3100 Phase 3 Trial Met Primary Efficacy Endpoint in Cervical Dysplasia Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Says China Partner Reported VGX-3100 Phase 3 Trial Met Primary Efficacy Endpoint in Cervical Dysplasia Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-22 05:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Inovio Pharmaceuticals (INO) said late Thursday that its China partner for VGX-3100, ApolloBio, revealed that the investigational immunotherapy met its primary efficacy endpoint in a phase 3 trial to treat cervical dysplasia, a precancerous condition that can progress to cervical cancer if left untreated.</p><p>The investigational DNA immunotherapy demonstrated overall favorable safety and tolerability profile, the company said.</p><p>ApolloBio will use trial results to support future regulatory submission of VGX-3100 in China, according to a statement.</p><p>Under the deal with ApolloBio, Inovio will receive up to $20 million upon achieving milestones related to the regulatory approval of the immunotherapy in certain territories, according to the company.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INO","symbol_name":"伊诺维奥制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2637357570","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637357570","pubTimestamp":1779397850,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Inovio Pharmaceuticals  said late Thursday that its China partner for VGX-3100, ApolloBio, revealed that the investigational immunotherapy met its primary efficacy endpoint in a phase 3 trial to treat cervical dysplasia, a precancerous condition that can progress to cervical cancer if left untreated.The investigational DNA immunotherapy demonstrated overall favorable safety and tolerability profile, the company said.ApolloBio will use trial results to support future regulatory submission of VGX-3100 in China, according to a statement.Under the deal with ApolloBio, Inovio will receive up to $20 million upon achieving milestones related to the regulatory approval of the immunotherapy in certain territories, according to the company.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INO":"伊诺维奥制药","BK4568":"美国抗疫概念","BK4583":"猴痘概念","BK4139":"生物科技"},"translate_title":"Inovio表示中国合作伙伴报告VGX-3100 3期试验在宫颈发育不良患者中达到了主要疗效终点","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":1},"content_text":"Inovio Pharmaceuticals (INO) said late Thursday that its China partner for VGX-3100, ApolloBio, revealed that the investigational immunotherapy met its primary efficacy endpoint in a phase 3 trial to treat cervical dysplasia, a precancerous condition that can progress to cervical cancer if left untreated.The investigational DNA immunotherapy demonstrated overall favorable safety and tolerability profile, the company said.ApolloBio will use trial results to support future regulatory submission of VGX-3100 in China, according to a statement.Under the deal with ApolloBio, Inovio will receive up to $20 million upon achieving milestones related to the regulatory approval of the immunotherapy in certain territories, according to the company.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637357570","isCrawlerRequest":true}